Tag Archive for: compass pathways
Psychedelic Business Spotlight: December 3
Business, Stock ReportsThis week in psychedelic business news: MAPS pioneers new funding structure; FDA green lights a Cybin study for Covid-19 distress; Compass Pathways gets new majority stakeholder.
Compass Pathways Releases Promising New Data from Landmark Psilocybin Therapy Trial
BusinessChief Medical Officer Dr. Guy Goodwin clarifies "COMP360 psilocybin therapy was generally well-tolerated" by patients with treatment-resistant depression, despite some adverse reactions from subjects in the study.
Psychedelic Business Spotlight: November 26
Business, Stock ReportsThis week in psychedelic business news: Compass Pathways files another patent; Seelos Therapeutics raises big money; Cybin makes psychedelic therapy more accessible in NYC.
Psychedelic Business Spotlight: November 12
Business, Stock ReportsThis week in psychedelic business news: two of the biggest players in the industry unveil big data; Numinus Wellness helps MAPS expand MDMA study; and Ketamine One announces IPO intention.
Largest Psilocybin Therapy Trial Ever Conducted Shows Depressive Symptoms Rapidly Reduce
Business, Research“A single dose of psilocybin generated a rapid response that lasted up to 12 weeks,” explains principal investigator Dr. David J. Hellerstein, who was evaluating Compass Pathways' novel drug formulation COMP360.
Psychedelic Business Spotlight: November 5
Business, Stock ReportsThis week in psychedelic business news: DEA grants Cybin a Schedule I manufacturing license; PharmaTher partners with Revive Therapeutics on microneedle patch technology; Mydecine patents nanotechnology.
Why We’re Excited About Compass Pathways’ New Clinical Trial Treating PTSD with Psilocybin
Business, Research
Compass Pathways (Nasdaq: CMPS) has announced the launch of a brand new psychedelic clinical trial, using psilocybin (the active ingredient in magic mushrooms) to treat PTSD, and there are multiple reasons to be excited about it.
The Phase-2…
Why Psychedelic Stocks Have Crashed in the Last 3 Months
BusinessOur resident psychedelic investor explains why psychedelic stocks are plummeting, and why patience can pay off big time.
Psychedelic Business Spotlight: September 17, 2021
Business, Stock ReportsThis week in psychedelic business news: Wesana teams up with MAPS, MindBio Therapeutics announces world-class research and drug development facility, and Awakn Life Sciences buys up ketamine clinics across the Nordics.
Psychedelic Business Spotlight: July 9, 2021
Business, Stock ReportsThis week in psychedelic business news: It’s all about partnerships and acquisitions designed to advance psychedelic therapies for depression, suicidal ideation, pain, and more.